Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib + Enzalutamide + ADT in Metastatic Prostate Cancer
NCT05873192Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2025; status: recruiting.
02
Drugs
talazoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05873192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873192.